|

Lenalidomide Clinical Trials

80 actively recruiting trials across 28 locations

▼ -1 trial since June 2026

Also known as: CC 5013, CC-5013, CC5013, CDC 501, EU Substance number SUB25389 +9 more

Pipeline

Early 1: 2Phase 1: 6Phase 2: 35Phase 3: 20Phase 4: 1Phase 1/2: 12Phase 2/3: 1

Top Sponsors

  • M.D. Anderson Cancer Center4
  • The First Affiliated Hospital with Nanjing Medical University3
  • Janssen Research & Development, LLC3
  • City of Hope Medical Center3
  • The Lymphoma Academic Research Organisation2

Indications

  • Cancer80
  • Multiple Myeloma35
  • Follicular Lymphoma6
  • Marginal Zone Lymphoma5
  • Multiple Myeloma (MM)3

Other36 trials

A Real-world Study of Obinutuzumab-based Therapy for Previously Untreated FL
A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myeloma
Phase 1/2
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma
Phase 1
A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma
Phase 2
A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma
Phase 1/2
A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Phase 3
A Study to Investigate Safety and Clinical Activity of Belantamab Mafodotin in Combination With Lenalidomide, Dexamethasone and Nirogacestat in Patients With Transplant Ineligible Newly Diagnosed Multiple Myeloma
Phase 1/2
A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant
Phase 3
Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients
Phase 2
Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma
Phase 2
Clinical Study on Anti-PD-1 Plus Lenalidomide and Azacitidine in Relapsed/Refractory Peripheral T-cell Lymphoma
Phase 2
Efficacy and Safety of Lenalidomide Plus CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
Phase 2
Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone Lymphoma
Phase 3
Efficacy and Safety of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCL
Phase 2
Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma
Phase 3
GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5
Phase 2
Glofitamab Combined With Lenalidomide in High Risk Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
Lenalidomide Plus Targeted Therapy and Immunotherapy for Refractory HCC
Phase 2
MIL62 Plus Lenalidomide for Patients With Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma (FL and MZL)
Phase 1/2
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Phase 2
Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma
Phase 3
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma
Phase 2
Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma
Phase 2
Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL
Phase 2
Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL
Phase 2
Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level
Phase 3
Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma
Phase 2
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
Phase 3
Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy
Phase 2
Risk Stratification and MRD-driven Maintenance for MM After ASCT
N/A
SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease
Phase 2
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
Phase 3
Study of Teclistamab in Combination in Elderly Patients With Multiple Myeloma
Phase 2
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma
Phase 2
Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection
Phase 4

Duarte, California4 trials

Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma

City of Hope Medical Center

Phase 1/2
Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma

City of Hope Medical Center

Phase 1/2
Testing the Combination of Anti-cancer Drugs Mosunetuzumab, Polatuzumab Vedotin, and Lenalidomide for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

City of Hope Comprehensive Cancer Center

Phase 1
Venetoclax, Lenalidomide and Rituximab in Patients With Previously Untreated Mantle Cell Lymphoma

City of Hope Medical center

Phase 1/2

Houston, Texas4 trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M D Anderson Cancer Center

Phase 2
Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

MD Anderson Cancer Center

Phase 2
Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

M D Anderson Cancer Center

Phase 2
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center

Phase 2

Birmingham, Alabama3 trials

A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)

Local Institution - 0225

Phase 3
Frontline T-cell Engager vs Autologous Stem Cell Transplant (ASCT) and Measurable Residual Disease (MRD)-Guided Sequential Intensification thERapy in Multiple Myeloma

University of Alabama at Birmingham

Phase 2
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

University of Alabama at Birmingham Cancer Center

Phase 3

Miami, Florida3 trials

A Study of Daratumumab

University of Miami Sylvester Cancer Center

Phase 3
ERd Combination Treatment in Newly Diagnosed Multiple Myeloma

University of Miami

Phase 2
Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse

University of Miami

Phase 2

Anchorage, Alaska2 trials

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Anchorage Associates in Radiation Medicine

Phase 3
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Anchorage Associates in Radiation Medicine

Phase 3

Gilbert, Arizona2 trials

A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma

Banner MD Anderson Cancer Center

Phase 3
Selinexor and Backbone Treatments of Multiple Myeloma Patients

Banner MD Anderson Cancer Center

Phase 1/2

Tucson, Arizona2 trials

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2
Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

Banner University Medical Center - Tucson

Phase 2

Denver, Colorado2 trials

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Colorado Blood Cancer Institute /ID# 273129

Phase 1/2
Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Colorado Blood Cancer Institute

Phase 2

Chicago, Illinois2 trials

Epcoritamab and Lenalidomide in Treating Patients With Refractory or Relapsed Immunodeficiency-Related Large B-Cell Lymphoma

Northwestern University

Phase 2
Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

University of Illinois at Chicago

Phase 2

Rochester, Minnesota2 trials

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Mayo Clinic in Rochester

Phase 1
Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mayo Clinic in Rochester

Phase 2

Mobile, Alabama1 trial

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)

GSK Investigational Site

Phase 3

Phoenix, Arizona1 trial

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Banner University Medical Center Tucson, University of Arizona

Phase 3

Scottsdale, Arizona1 trial

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Mayo Clinic Hospital Scottsdale /ID# 278349

Phase 2/3

Alhambra, California1 trial

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

Global Oncology, Inc.

Phase 1

Berkeley, California1 trial

A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Alta Bates Summit Medical Center

Phase 3

Fresno, California1 trial

Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma

UCSF Fresno /ID# 264712

Phase 3

La Jolla, California1 trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Scripps Clinic Torrey Pines

Phase 1

Los Angeles, California1 trial

A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma

David Geffen School of Medicine at UCLA

Phase 3

West Hollywood, California1 trial

Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma

Berenson Cancer Center

Early 1

New Haven, Connecticut1 trial

Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone Lymphoma

Yale Cancer Center

Phase 2

Jupiter, Florida1 trial

A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

Jupiter Medical Center/Anderson Family Cancer Institute

Phase 3

Atlanta, Georgia1 trial

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Emory Winship Cancer Institute

Phase 1/2

Augusta, Georgia1 trial

VitD3 Supplementation in Patients With Multiple Myeloma

Georgia Cancer Center at Augusta University

Early 1

Boston, Massachusetts1 trial

A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma

Dana Farber Cancer Institute

Phase 1/2

Minneapolis, Minnesota1 trial

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Masonic Cancer Center

Phase 2

East Setauket, New York1 trial

A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas

North Shore Hematology Oncology Associates

Phase 1

Chapel Hill, North Carolina1 trial

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center

Phase 2

Wilson, North Carolina1 trial

Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

Regional Oncology Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.